Dyne Therapeutics
Dyne Therapeutics Inc is a clinical-stage biotechnology enterprise headquartered in Waltham, Massachusetts. The company specializes in the discovery and development of novel oligonucleotide therapeutics designed to treat genetically driven rare muscle diseases. Its proprietary FORCE platform leverages antibody-antigen interactions to deliver modern genetic medicines directly into muscle tissue, targeting conditions such as myotonic dystrophy type 1 and Duchenne muscular dystrophy. Principal revenue is currently earned through research grants, biopharmaceutical collaborations, and capital financing agreements. The enterprise serves patients suffering from debilitating neuromuscular disorders. Dyne Therapeutics Inc is publicly listed on the Nasdaq Stock Market.
8 of the funds FundTelligence covers report a position in Dyne Therapeutics.
- Legal name
- DYNE THERAPEUTICS INC
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 8
- Exposure themes
- Genetic Medicine, Precision Medicine & Genomics, RNA Therapeutics
Funds holding Dyne Therapeutics
- JPM US Small Cap Growth Fund — JPM · 0.76 % (full portfolio disclosed, June 2026)
- Franklin Biotechnology Discovery Fund — Franklin Templeton · 0.68 % (full portfolio disclosed, September 2026)
- JPM Global Healthcare Fund — JPM · 0.66 % (full portfolio disclosed, June 2026)
- T. Rowe Price US Smaller Companies Equity Fund — T. Rowe Price · 0.49 % (full portfolio disclosed, September 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.22 % (full portfolio disclosed, October 2026)
- Handelsbanken Global SMB Index Criteria — Handelsbanken · 0.03 % (full portfolio disclosed, October 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.02 % (partially disclosed portfolio, June 2026)
- DNB Global Enhanced Small Cap — DNB · 0.02 % (full portfolio disclosed, September 2026)